Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020

By Colin Kellaher

Avidity Biosciences Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to its AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy.

The San Diego biopharmaceutical company said AOC 1020 is currently in a Phase 1/2 study in adults with the rare, hereditary muscle-weakening condition, adding that it plans to share data from a preliminary assessment of about half of study participants in the first half of 2024.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

01-18-23 0950ET